Drug Trial Radar · NCT06722430
A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Nov 13, 2024
Primary completion
Jan 13, 2025
Study completion Jan 13, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is to assess the change of itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety, and tolerability of a single dose of icalcaprant in healthy participants.
Conditions
- Healthy Volunteer
Interventions
IcalcaprantDrug
Oral capsule
Itraconazole (ITZ)Drug
Oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of IcalcaprantTime frame: Up to approximately 14 days
- Time to Cmax (Tmax) of IcalcaprantTime frame: Up to approximately 14 days
- Terminal Phase Elimination Rate Constant (Beta) of IcalcaprantTime frame: Up to approximately 14 days
- Terminal Phase Elimination Half-Life (t1/2) of IcalcaprantTime frame: Up to approximately 14 days
- Area under the plasma concentration-time curve (AUC) of IcalcaprantTime frame: Up to approximately 14 days
- Area under the plasma concentration-time curve from time 0 until the last measurable Concentration (AUCt) of IcalcaprantTime frame: Up to approximately 14 days
- Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of IcalcaprantTime frame: Up to approximately 14 days
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 47 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 271617
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.